Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Cash & Current Investments (2016 - 2025)

Assembly Biosciences (ASMB) has 11 years of Cash & Current Investments data on record, last reported at $22.5 million in Q3 2025.

  • For Q3 2025, Cash & Current Investments fell 20.8% year-over-year to $22.5 million; the TTM value through Sep 2025 reached $22.5 million, down 20.8%, while the annual FY2024 figure was $112.1 million, 13.95% down from the prior year.
  • Cash & Current Investments reached $22.5 million in Q3 2025 per ASMB's latest filing, down from $75.0 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $214.9 million in Q1 2021 and bottomed at $18.1 million in Q1 2024.
  • Average Cash & Current Investments over 5 years is $81.3 million, with a median of $73.0 million recorded in 2023.
  • Peak YoY movement for Cash & Current Investments: soared 407.69% in 2021, then plummeted 78.37% in 2022.
  • A 5-year view of Cash & Current Investments shows it stood at $146.6 million in 2021, then tumbled by 37.52% to $91.6 million in 2022, then soared by 42.18% to $130.2 million in 2023, then fell by 13.95% to $112.1 million in 2024, then tumbled by 79.89% to $22.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $22.5 million in Q3 2025, $75.0 million in Q2 2025, and $91.0 million in Q1 2025.